Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | YAP1 | P46937 | 2/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.39 |
| ▸ | STS | P08842 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2254528 | 0.83 | ESR2 (0.51) | ESR2NR1H2GPR119POLBPRMT5 | |
| SCHEMBL2256587 | 0.83 | ESR2 (0.51) | ESR2NR1H2GPR119POLBPRMT5 | |
| SCHEMBL2254895 | 0.82 | ESR2 (0.44) | ESR2NR1H2GPR119POLBPRMT5 | |
| SCHEMBL2253554 | 0.82 | ESR2 (0.50) | ESR2NR1H2GPR119POLBPRMT5 | |
| SCHEMBL2254913 | 0.82 | ESR2 (0.50) | ESR2NR1H2GPR119POLBPRMT5 | |
| SCHEMBL2255061 | 0.82 | ESR2 (0.50) | ESR2NR1H2GPR119POLBPRMT5 | |
| SCHEMBL2253767 | 0.82 | ESR2 (0.43) | ESR2NR1H2GPR119OPRD1OPRK1 | |
| SCHEMBL507908 | 0.80 | YAP1 (0.46) | ESR2GPR119YAP1PRMT5 | |
| SCHEMBL14115666 | 0.79 | ESR2 (0.49) | ESR2NR1H2GPR119POLBPRMT5 | |
| SCHEMBL3961806 | 0.79 | ESR2 (0.46) | ESR2NR1H2GPR119POLBPRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7994163-B2 | e.g. 3-tert-Butoxycarbonyl-7-chloro-6-chloromethyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine; serotonin receptor agonist; antidepressant, anxiolytic agent; obesity, obsessive compulsive disorder | ELI LILLY AND COMPANY (US) | 2011-08-09 | — | — | US | disclosed |
| EP-1924560-B1 | 6-SUBSTITUTED- 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | LILLY CO ELI (US) | 2009-08-05 | — | — | EP | disclosed |
| US-20080255092-A1 | 6-Substituted-2,3,4,5-Tetrahydro-1H-Benzo[d]Azepines as 5-Ht2c Receptor Agonists | ELI LILLY AND COMPANY | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255092-A1 | 6-Substituted-2,3,4,5-Tetrahydro-1H-Benzo[d]Azepines as 5-Ht2c Receptor Agonists | HTR2C, HTR3C, HTR3A | ESR2 256/4885NR1H2 197/4885GPR119 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.